No Avail | Shadow Protectionism @No_Avail | Uploaded January 2019 | Updated October 2024, 3 hours ago.
The paper: cepr.net/images/stories/reports/ip-2018-10.pdf

Bayh–Dole Act: en.wikipedia.org/wiki/Bayh%E2%80%93Dole_Act

Dean Baker's work at CEPR: cepr.net/blogs/beat-the-press

Baker's other archives: rwer.wordpress.com/author/deanbaker1

Baker's "Rigged" paper: deanbaker.net/images/stories/documents/Rigged.pdf

Some of the references from the IP paper:

1. Generic Drug Access & Savings in the U.S: accessiblemeds.org/resources/blog/2017-generic-drug-access-and-savings-us-report

2. Rents & Inefficiency in the Patent & Copyright System: cepr.net/images/stories/reports/rents-inefficiency-patents-2016-08.pdf?v=2

3. Innovation, Intellectual Property, and Development: cepr.net/images/stories/reports/baker-jayadev-stiglitz-innovation-ip-development-2017-07.pdf

4. Drug Patents: The Evergreening Problem: ncbi.nlm.nih.gov/pmc/articles/PMC3680578

5. Price Declines after Branded Medicines Lose Exclusivity in the U.S.: iqvia.com/-/media/iqvia/pdfs/institute-reports/price-declines-after-branded-medicines-lose-exclusivity-in-the-us.pdf

For the remaining references, see the bottom section of the paper. (Can't include all the references here, as I've run out of space)